Broad corrections across pharmaceutical and biotechnology equity sectors are often triggered by macroeconomic shifts, such as changing interest rate expectations, legislative debates concerning drug pricing policies, or disappointing clinical trial updates from major industry bellwethers. Additionally, sector-wide profit-taking following strong rallies and investor rotation into cyclical market segments can lead to temporary, synchronized downward momentum across major healthcare and pharmaceutical indices.